A New Generation of Anti-Viral Vaccines for Aquaculture Using Nanotechnology

Award Information
Agency:
Department of Commerce
Amount:
$197,855.00
Program:
SBIR
Contract:
DG133R-04-CN-0160
Solitcitation Year:
2003
Solicitation Number:
NOAA-2003-1
Branch:
N/A
Award Year:
2004
Phase:
Phase II
Agency Tracking Number:
2003-70
Solicitation Topic Code:
8.4.6
Small Business Information
ProFishent Incorporated
17306 NE 26th Street, Redmond, WA, 98052
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 David Powell
 VP, R&D
 (425) 883-9896
 davidp@profishent.com
Business Contact
 Roger Palm
Title: President
Phone: (425) 883-9896
Email: rogerp@profishent.com
Research Institution
N/A
Abstract
Although companies based outside the U.S. have tested and, in some cases, sold basic anti-viral vaccines to aquaculture producers, practicing veterinarians and virologists have been unimpressed by their extremely limited effectiveness (J. Mullins, pers. comm. 2002; J. Winton, pers. comm. 2004). The consensus is that new approaches are urgently needed to develop viral vaccines that do not rely on DNA technology. ProFishent will apply advances in nanotechnology to the design and construction of efficacious immersion and injection vaccines to prevent mortalities from viruses and, potentially, other intracellular pathogens. Proprietary nanoparticles will be combined with model viruses (ISAV and IHNV) to create potent immunostimulatory complexes. Vaccine prototypes will be optimized and compared to traditional formulations for their ability to stimulate immunity and to protect rainbow trout and Atlantic salmon from laboratory challenges with live pathogens. Fluorescent, antigen-coated particles will also be used to observe the effect of size on uptake and transport by the immune system.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government